title: Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease.
abstract: Dopaminergic medications could increase the occurrence of a set of dysregulated behaviours in Parkinson's disease (PD), including reward-seeking behaviours (pathological gambling, hypersexuality, compulsive shopping, binge eating, reckless driving), punding and compulsive medication use. We report a preliminary evaluation of a questionnaire to assess the presence of these impulsive-compulsive behaviours associated to dopamine replacement therapy in PD. We screened 38 patients and their caregivers, comparing dopamine dysregulation syndrome (DDS) patients and non-DDS patients. The questionnaire was well accepted and demonstrated a preliminary good discriminant validity (p = 0.000). In addition, clinically relevant dysregulated condition is associated with a younger age (p = 0.006), younger age at disease onset (p = 0.001), levodopa-equivalent daily dose (p = 0.029), UPDRS III (p = 0.021), increased global psychopathology (interpersonal sensitivity and psychoticism), and differences in our inventory (p = 0.000). These preliminary results suggest that the DDS-PC inventory could help to identify patients experiencing impulsive-compulsive behaviours associated to DDS.
authors.affiliation: Division on Addiction, Hospital of Cortemaggiore, Azienda Unità Sanitaria Locale of Piacenza, Piacenza, Italy. silvia.cabrini@libero.it
authors.forename: Silvia
authors.initials: S
authors.lastname: Cabrini
authors.forename: Mario
authors.initials: M
authors.lastname: Baratti
authors.forename: Flavio
authors.initials: F
authors.lastname: Bonfà
authors.forename: Giulio
authors.initials: G
authors.lastname: Cabri
authors.forename: Elena
authors.initials: E
authors.lastname: Uber
authors.forename: Maurizio
authors.initials: M
authors.lastname: Avanzi
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017028:Caregivers; D003193:Compulsive Personality Disorder / Q000139:chemically induced / Q000523:psychology; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000523:psychology*; D004298:Dopamine / Q000502:physiology*; D015259:Dopamine Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005715:Gambling / Q000209:etiology / Q000523:psychology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D010556:Personality Tests; D011594:Psychometrics; D012372:ROC Curve; D012201:Reward; D011795:Surveys and Questionnaires
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents; D007980:Levodopa; D004298:Dopamine